2022 Volume 47 Issue 4 Pages 534-544
We encountered two cases of unresectable advanced gastric cancer with peritoneal dissemination that responded to fluorouracil + folinate + oxaliplatin (FOLFOX) therapy. Case 1 was a 66-year-old man with anorexia and abdominal pain who was diagnosed as having type 4 gastric cancer and referred to our hospital. He had esophageal infiltration and peritoneal dissemination. Although it was considered difficult to improve the oral intake by sigh surgery, he was started on FOLFOX therapy as his general condition was well maintained. Partial response, based on the RECIST criteria, was achieved, the ascites disappeared, and the patient resumed oral intake. Case 2 was a 73-year-old woman with a history of poor oral intake who was diagnosed as having type 4 gastric cancer and referred to our hospital. Laparoscopic exploration revealed multiple nodules of peritoneal disseminations, and FOLFOX therapy was started. Partial response was achieved, the ascites disappeared, and the patient resumed oral intake. From the viewpoint of improving the QOL and prognosis, FOLFOX therapy is considered as being a useful and effective therapeutic option for patients with unresectable advanced gastric cancer and peritoneal dissemination with difficulty in oral intake.
